Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹)
June 13, 2024 19:58 ET
|
Opthea Limited
Fully underwritten Retail Entitlement Offer to raise a further approximately A$55.9m (US$36.9m1) will open on 19 June 2024 and close at 5:00 pm (Melbourne time) on 10 July 2024 MELBOURNE,...
Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹)
June 11, 2024 21:13 ET
|
Opthea Limited
Financing extends Opthea’s cash runway through Phase 3 topline data readout for both pivotal trials of sozinibercept in wet AMD Phase 3 topline data readout accelerated for COAST to early Q2...
Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)
June 11, 2024 08:00 ET
|
Predictive Oncology Inc.
Company files expansive intellectual property protection for “Membrane Protein Factory” to produce purified and biologically active membrane proteins for drug development External sources value...
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2024 18:35 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted...
SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML
June 10, 2024 08:40 ET
|
SELLAS Life Sciences Group, Inc.
- 30 Patients Relapsed or Refractory to Venetoclax-Based Regimens Enrolled Ahead of Schedule - - Overall Response Rate (ORR) of 33% and 50% Achieved to Date in 60 mg QW and 30 mg BIW Cohorts,...
Nusano Names D. Scott Holbrook as Chairman of its Board
June 07, 2024 08:00 ET
|
Nusano, Inc.
VALENCIA, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Nusano, Inc., a physics company transforming the production of medical radioisotopes, today announced industry veteran D. Scott Holbrook as chairman...
Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery
June 04, 2024 08:42 ET
|
Predictive Oncology Inc.
Predictive Oncology’s organ-specific in vitro models are designed to better mimic the physiological environment of human tissue The 3D cell culture market is projected to grow by more than 14%...
Elevar Therapeutics Reports Landmark Median Overall Survival of 23.8 Months in First-Line Treatment for Unresectable Hepatocellular Carcinoma
May 30, 2024 07:00 ET
|
Elevar Therapeutics
Phase 3 CARES-310 study found combination of camrelizumab and rivoceranib continued to show sustained long-term survival compared with sorafenib as a first-line treatment for uHCCFinal analysis...
Nusano Expands Executive Management to Support Q1 2025 Radioisotope Commercialization
May 29, 2024 08:00 ET
|
Nusano, Inc.
VALENCIA, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Nusano, Inc., a physics company transforming the production of medical radioisotopes, today announced the addition of three executives to enhance...
Predictive Oncology Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 28, 2024 07:00 ET
|
Predictive Oncology Inc.
PITTSBURGH, May 28, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that positive results from a retrospective...